SCHEMBL1629653

SCHEMBL1629653

CC(C)n1cc(-c2ccc(/C=N\O)cc2)c2ccc(NS(C)(=O)=O)cc21

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PGR P06401 8/20 0.66
NR3C1 P04150 7/20 0.66
NR3C2 P08235 7/20 0.66
AR P10275 6/20 0.59
SCN9A Q15858 5/20 0.40
SCN5A Q14524 2/20 0.40
ALDH2 P05091 1/20 0.37
KAT2B Q92831 1/20 0.37
BRD4 O60885 2/20 0.35
ALDH1A1 P00352 1/20 0.35
AURKA O14965 1/20 0.35
KDR P35968 1/20 0.35
AURKB Q96GD4 1/20 0.35
IKBKB O14920 1/20 0.34
CHUK O15111 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1629654 1.00 PGR (0.66) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1629263 0.89 PGR (0.57) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1629264 0.89 PGR (0.57) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1629465 0.87 PGR (0.71) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1629873 0.85 PGR (0.66) PGRNR3C1NR3C2ARSCN9A
SCHEMBL14116514 0.85 PGR (0.66) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1629874 0.85 PGR (0.66) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1630826 0.85 PGR (0.74) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1631048 0.82 PGR (0.74) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1631091 0.82 PGR (0.73) PGRNR3C1NR3C2ARSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979314-B1 INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS LILLY CO ELI (US) 2013-01-09 EP disclosed
US-7932284-B2 Indole sulfonamide modulators of progesterone receptors ELI LILLY AND COMPANY (US) 2011-04-26 US disclosed
US-20090069400-A1 Indole Sulfonamide Modulators of Progesterone Receptors ELI LILLY AND COMPANY 2009-03-12 US disclosed
EP-1979314-A2 INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS Eli Lilly & Company (US) 2008-10-15 EP disclosed
WO-2007087488-A9 INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS LILLY CO ELI (US) 2008-08-28 WO disclosed
WO-2007087488-A2 INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS ELI LILLY AND COMPANY (US) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069400-A1 Indole Sulfonamide Modulators of Progesterone Receptors PGR, NPSR1, PRLHR PGR 1/4885NR3C1 63/4885NR3C2 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.